These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 37820563)

  • 1. Response to letter entitled: letter comments on: Pathologist-initiated reflex testing for biomarkers in non-small-cell lung cancer: expert consensus on the rationale and considerations for implementation.
    Gosney JR; Peters S
    ESMO Open; 2023 Oct; 8(5):101828. PubMed ID: 37820563
    [No Abstract]   [Full Text] [Related]  

  • 2. Pathologist-initiated reflex testing for biomarkers in non-small-cell lung cancer: expert consensus on the rationale and considerations for implementation.
    Gosney JR; Paz-Ares L; Jänne P; Kerr KM; Leighl NB; Lozano MD; Malapelle U; Mok T; Sheffield BS; Tufman A; Wistuba II; Peters S
    ESMO Open; 2023 Aug; 8(4):101587. PubMed ID: 37356358
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular testing for advanced non-small cell lung cancer in Malaysia: Consensus statement from the College of Pathologists, Academy of Medicine Malaysia, the Malaysian Thoracic Society, and the Malaysian Oncological Society.
    Rajadurai P; Cheah PL; How SH; Liam CK; Annuar MAA; Omar N; Othman N; Marzuki NM; Pang YK; Bustamam RSA; Tho LM
    Lung Cancer; 2019 Oct; 136():65-73. PubMed ID: 31446227
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [When to Test in Biomarker-stratified Therapy of Non-small Cell Lung Cancer - Biomarker-stratified Therapy of Non-small Cell Lung Cancer: When and What to Test?].
    Griesinger F; Thomas M
    Pneumologie; 2021 Sep; 75(9):641-643. PubMed ID: 34525486
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A systematic review and Canadian consensus recommendations on the use of biomarkers in the treatment of non-small cell lung cancer.
    Ellis PM; Blais N; Soulieres D; Ionescu DN; Kashyap M; Liu G; Melosky B; Reiman T; Romeo P; Shepherd FA; Tsao MS; Leighl NB
    J Thorac Oncol; 2011 Aug; 6(8):1379-91. PubMed ID: 21709590
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Consensus recommendations for optimizing biomarker testing to identify and treat advanced
    Cheema PK; Gomes M; Banerji S; Joubert P; Leighl NB; Melosky B; Sheffield BS; Stockley T; Ionescu DN
    Curr Oncol; 2020 Dec; 27(6):321-329. PubMed ID: 33380864
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictive markers in lung cancer: a few hints for the practicing pathologist.
    Barbareschi M; Barberis M; Buttitta F; Doglioni C; Fiorentino M; Fontanini G; Franco R; Marchetti A; Rossi G; Troncone G
    Pathologica; 2018 Mar; 110(1):29-38. PubMed ID: 30259911
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PD-L1 immunohistochemistry in clinical diagnostics of lung cancer: inter-pathologist variability is higher than assay variability.
    Brunnström H; Johansson A; Westbom-Fremer S; Backman M; Djureinovic D; Patthey A; Isaksson-Mettävainio M; Gulyas M; Micke P
    Mod Pathol; 2017 Oct; 30(10):1411-1421. PubMed ID: 28664936
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Updates Regarding Biomarker Testing for Non-Small Cell Lung Cancer: Considerations from the National Lung Cancer Roundtable.
    Kim ES; Roy UB; Ersek JL; King J; Smith RA; Martin N; Martins R; Moore A; Silvestri GA; Jett J
    J Thorac Oncol; 2019 Mar; 14(3):338-342. PubMed ID: 30709747
    [No Abstract]   [Full Text] [Related]  

  • 10. Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer.
    Kerr KM; Bubendorf L; Edelman MJ; Marchetti A; Mok T; Novello S; O'Byrne K; Stahel R; Peters S; Felip E;
    Ann Oncol; 2014 Sep; 25(9):1681-1690. PubMed ID: 24718890
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [When to test in biomarker-stratified therapy of non-small cell lung cancer - Biomarker-stratified therapy of Non-small cell lung cancer: when and what to test?].
    Griesinger F; Thomas M
    Dtsch Med Wochenschr; 2021 Apr; 146(8):559-561. PubMed ID: 33853174
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Utility of Reflex Ordered Testing for Molecular Biomarkers in Lung Adenocarcinoma.
    Anand K; Phung TL; Bernicker EH; Cagle PT; Olsen RJ; Thomas JS
    Clin Lung Cancer; 2020 Sep; 21(5):437-442. PubMed ID: 32600793
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interpathologist Diagnostic Agreement for Non-Small Cell Lung Carcinomas Using Current and Recent Classifications.
    Funkhouser WK; Hayes DN; Moore DT; Funkhouser WK; Fine JP; Jo H; Nikolaishvilli-Feinberg N; Eeva M; Grilley-Olson JE; Banks PM; Graziano P; Boswell EL; Elmberger G; Raparia K; Hart CF; Sholl LM; Nolan NJ; Fritchie KJ; Pouagare E; Allen TC; Volmar KE; Biddinger PW; Kleven DT; Papez MJ; Spencer DV; Rekhtman N; Mino-Kenudson M; Hariri L; Driver B; Cagle PT
    Arch Pathol Lab Med; 2018 Dec; 142(12):1537-1548. PubMed ID: 29708428
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Expert consensus on PD-L1 expression testing in non-small-cell lung cancer in China].
    ; ;
    Zhonghua Zhong Liu Za Zhi; 2020 Jul; 42(7):513-521. PubMed ID: 32842436
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biomarker testing in advanced non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology.
    Felip E; Concha Á; de Castro J; Gómez-Román J; Garrido P; Ramírez J; Isla D; Sanz J; Paz-Ares L; López-Ríos F
    Clin Transl Oncol; 2015 Feb; 17(2):103-12. PubMed ID: 25351175
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PD-L1 expression by Tumor Proportion Score (TPS) and Combined Positive Score (CPS) are similar in non-small cell lung cancer (NSCLC).
    De Marchi P; Leal LF; Duval da Silva V; da Silva ECA; Cordeiro de Lima VC; Reis RM
    J Clin Pathol; 2021 Nov; 74(11):735-740. PubMed ID: 33589532
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Screen of ALK-positive non-small cell lung cancer by routine immunohistochemistry: an expert consensus].
    Consensus Group for screen of ALK-positive non-small cell lung cancer by routine immunohistochemistry
    Zhonghua Bing Li Xue Za Zhi; 2015 Jul; 44(7):476-9. PubMed ID: 26705037
    [No Abstract]   [Full Text] [Related]  

  • 18. Evaluation of an online training tool for scoring programmed cell death ligand-1 (PD-L1) diagnostic tests for lung cancer.
    Jasani B; Bänfer G; Fish R; Waelput W; Sucaet Y; Barker C; Whiteley JL; Walker J; Hovelinck R; Diezko R
    Diagn Pathol; 2020 Apr; 15(1):37. PubMed ID: 32303234
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Chinese Expert Consensus on Next Generation Sequencing Diagnosis 
for Non-small Cell Lung Cancer (2020 Edition)].
    Chinese Society of Clinical Oncology, Expert Committee on Non-small Cell Lung Cancer
    Zhongguo Fei Ai Za Zhi; 2020 Sep; 23(9):741-761. PubMed ID: 32957170
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biomarker testing in non-small cell lung cancer: to move forward with quality.
    Stahel R
    Clin Transl Oncol; 2012 May; 14(5):321-2. PubMed ID: 22551535
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.